Company
About us
History
Leaderships
Team
EU grants
Requests for Proposal
Sustainability – ESG
Bussines strategy
Quality policy
Virtual Tour
Investors
Corporate documents
Shareholders and shares
Periodic reports
Current reports
Sustainability reports
Corporate governance at Mabion
Financial data
For Investors
Calendar
Resources
Science Hub
Press releases
News
Events
Media kit
Services
Process Development
Analytics
Drug Substance Manufacturing
Contact
Contact form
Contact for investors
Contact for media
Careers
Science News
Resources
Drug substance
PD-1 Antibody Development Programs for Cancer Immunotherapy
Bispecific antibody
,
Cancer
,
Drug substance
,
Manufacturing
,
Monoclonal antibody
High-yield mAbs Manufacturing Platform Approach
Drug substance
,
Mabion
,
Manufacturing
,
Monoclonal antibody
Robust Scale-down Model for Reliable Upstream Bioprocessing Scale-up
Drug substance
,
GMP
,
Mabion
,
Manufacturing
Bioprocess Optimization Across Upstream and Downstream Processing
Drug development
,
Drug product
,
Drug substance
,
Manufacturing
Mass Spectrometry in Peptide and Protein Analysis
Analytics
,
Drug substance
,
Proteins
Mammalian Cell Lines as a Platform for Protein Vaccine Production
Cell culture
,
Drug substance
,
Manufacturing
,
Proteins
,
Vaccines
Qualitative Analysis of Host Cell Proteins using Mass Spectrometry
Analytics
,
Drug development
,
Drug product
,
Drug substance
Bioprocess Operation Modes and Advanced Bioreactor Technology
Cell culture
,
Drug substance
,
Manufacturing
Metabolite and nutrient analysis as crucial components for optimal CHO cell culture upstream process
Cell culture
,
Drug substance
,
Manufacturing
1
2
Next